---
title: "CUE.US (CUE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CUE.US/news.md"
symbol: "CUE.US"
name: "CUE.US"
parent: "https://longbridge.com/en/quote/CUE.US.md"
datetime: "2026-05-19T21:39:59.897Z"
locales:
  - [en](https://longbridge.com/en/quote/CUE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CUE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CUE.US/news.md)
---

# CUE.US (CUE.US) — Related News

### [Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments | CUE Stock News](https://longbridge.com/en/news/286460513.md)
*2026-05-14T12:07:00.000Z*
> Cue Biopharma reported its Q1 2026 financial results, highlighting strategic developments including a $30 million privat

### [Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CUE Stock News](https://longbridge.com/en/news/285634071.md)
*2026-05-07T15:07:00.000Z*
> Cue Biopharma, Inc. (Nasdaq: CUE) announced the grant of inducement equity awards to seven new employees, including CEO 

### [Pre-market hot trades in US stocks: Circle up 4.97% in pre-market; Cue BioPharma down 4.83% in pre-market](https://longbridge.com/en/news/285048679.md)
*2026-05-04T09:02:32.000Z*
> Circle pre-market up 4.97%; Cue BioPharma pre-market down 4.83%; Credit Suisse High Yield Credit Fund pre-market up 244.

### [Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?](https://longbridge.com/en/news/284868524.md)
*2026-05-01T05:40:00.000Z*
> Cue Biopharma Inc. (CUE) shares surged 67.57% to $24.70 after announcing a $30 million private investment, a Phase 2 ant

### [Cue Biopharma (CUE) surges nearly 80% intraday](https://longbridge.com/en/news/284906416.md)
*2026-05-01T13:56:11.000Z*
> Cue Biopharma（CUE.US）现价 $26.500，当日 +79.78%，盘中涨势显著，市值 0.92 亿。公司专注于免疫药物研发，股价因盘前及盘后持续上涨引发关注。近日媒体报道公司盘前大涨超过 65%，市场聚焦其潜在临床进展和

### [Cue Biopharma Licenses Anti-IgE Asset From Ascendant; $15M Upfront, Up to $676.5M in Milestones](https://longbridge.com/en/news/284906657.md)
*2026-05-01T13:53:01.000Z*
> Cue Biopharma has secured an exclusive license for the anti-IgE asset Ascendant-221 from Ascendant Health Sciences, invo